一、持续督导工作情况 广发证券股份有限公司 关于广州禾信仪器股份有限公司 2023 年度持续督导跟踪报告 根据《证券发行上市保荐业务管理办法》、《上海证券交易所科创板股票上 市规则》等有关法律、法规的规定，广发证券股份有限公司（以下简称"广发证 券"、"保荐机构"）作为广州禾信仪器股份有限公司（以下简称"禾信仪器"、 "公司"）2023 年度的持续督导机构，负责禾信仪器 2023 年度的持续督导工作， 并出具本年度持续督导跟踪报告。 2023 年度，广发证券对禾信仪器的持续督导工作情况总结如下： | 序号 | 工作内容 | 实施情况 | | --- | --- | --- | | | 建立健全并有效执行持续督导工作制度，并 | 保荐机构已建立健全并有效执行 | | 1 | 针对具体的持续督导工作制定相应的工作计 | 了持续督导制度，已制定了相应的 | | | 划。 | 工作计划。 | | 2 | 根据中国证监会相关规定，在持续督导工作 | 保荐机构已与禾信仪器签订《保荐 | | | 开始前，与上市公司或相关当事人签署持续 | 协议》，该协议已明确了双方在持 | | | 督导协议，明确双方在持续督导期间的权利 ...

Financial Performance - The company's operating revenue for Q1 2024 was ¥46,603,068.17, representing a decrease of 18.12% compared to the same period last year[5]. - The net profit attributable to shareholders was -¥15,019,069.20, with a basic and diluted earnings per share of -¥0.21, indicating a significant loss[5]. - Total operating revenue for Q1 2024 was CNY 46,603,068.17, a decrease of 18.1% compared to CNY 56,915,996.54 in Q1 2023[17]. - Net loss for Q1 2024 was CNY 16,406,836.05, compared to a net loss of CNY 17,912,045.86 in Q1 2023, indicating an improvement of 8.4%[18]. - The total equity attributable to shareholders decreased to CNY 420,869,055.99 in Q1 2024 from CNY 435,255,984.38 in Q1 2023, a decrease of 3.3%[16]. - The company reported a total profit loss of CNY 10,228,241.59 in Q1 2024, down from CNY 15,880,265.76 in Q1 2023, marking a 35.7% improvement[28]. Research and Development - R&D investment totaled ¥11,443,082.59, down 38.81% year-on-year, with R&D expenses accounting for 24.55% of operating revenue, a decrease of 8.31 percentage points[5]. - The company is shifting its R&D focus towards key projects and improving efficiency, leading to a reduction in the number of ongoing projects and optimization of resource allocation[8]. - Research and development expenses decreased to CNY 11,443,082.59 in Q1 2024 from CNY 18,702,240.07 in Q1 2023, a reduction of 38.9%[17]. - Research and development expenses for Q1 2024 were CNY 9,049,773.87, down from CNY 14,087,002.53 in Q1 2023, indicating a reduction of 35.7%[27]. Assets and Liabilities - Total assets at the end of the reporting period were ¥1,053,421,123.64, a decline of 2.56% from the end of the previous year[6]. - The company's total assets amounted to RMB 1,053,421,123.64, a decrease from RMB 1,081,138,237.91 as of December 31, 2023[14]. - The company's total liabilities decreased to CNY 651,507,597.63 in Q1 2024 from CNY 663,450,016.66 in Q1 2023, a decline of 1.4%[16]. - The company's total liabilities decreased to CNY 528,485,396.87 from CNY 556,894,338.19 year-over-year[25]. Cash Flow - Cash inflow from operating activities totaled CNY 92,364,865.56 in Q1 2024, an increase from CNY 65,656,368.94 in Q1 2023[21]. - The net cash flow from operating activities was -CNY 14,639,831.57, an improvement from -CNY 64,282,832.85 in the previous year[22]. - Cash flow from operating activities generated a net inflow of CNY 6,641,870.16 in Q1 2024, a significant recovery from a net outflow of CNY 57,341,846.64 in Q1 2023[30]. - Cash outflows from operating activities totaled CNY 106,477,830.74 in Q1 2024, a decrease from CNY 114,231,848.66 in Q1 2023, reflecting improved cost management[30]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 3,798[10]. - The company has a significant shareholder structure, with the top 10 shareholders holding a combined total of 69,000,000 shares, representing a substantial portion of the company's equity[12]. - The company is actively involved in investment activities, with several investment funds holding shares, including Shanghai Ge Ru Private Fund Management Co., which holds 381,000 shares[12]. Management and Audit - The company has not conducted an audit for the Q1 financial statements[5]. - The management has assured the accuracy and completeness of the financial report, taking legal responsibility for its content[3]. - The company has not reported any significant changes in its operational strategies or future outlook during the conference call[12]. Future Outlook - The company plans to continue focusing on improving operational efficiency and exploring new market opportunities to enhance future performance[32].

您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://ace.no/.gov.cn) "进行创 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://ace.mol.gov.cn）"进行创 。 " Thornton t 1 1 1 1 内部控制审计报告 致同审字(2024)第 440A015321 号 广州禾信仪器股份有限公司 二〇二三年度 内部控制审计报告 致同会计师 骑线 致同会计师事务所 (特殊普通合伙) 广州禾信仪器股份有限公司全体股东: 按照《企业内部控制审计指引》及中国注册会计师执业准则的相关要求, 我们审计了广州禾信仪器股份有限公司（以下简称"禾信仪器"）2023 年 12 月 31日的财务报告内部控制的有效性。 一、企业对内部控制的责任 按照《企业内部控制基本规范》、《企业内部控制应用指引》、《企业 内部控制评价指引》的规定,建立健全和有效实施内部控制,并评价其有效 性是禾信仪器董事会的责任。 二、注册会计师的责任 我们的责任是在实施审计工作的基础上,对财务报告内部控制的有效性 发表审计意见,并对注意到的非财务报告内部控制的重大缺陷进行披露。 三、内部控制的 ...

广州禾信仪器股份有限公司 2023年度独立董事述职报告（刘桂雄） 2023年度，作为广州禾信仪器股份有限公司（以下简称"公司"）的独立董 事，本人严格按照《中华人民共和国公司法》《中华人民共和国证券法》《上市公 司治理准则》《上市公司独立董事管理办法》《上海证券交易所科创板股票上市规 则》等法律法规，以及《广州禾信仪器股份有限公司章程》（以下简称"《公司章 程》"）和《广州禾信仪器股份有限公司独立董事工作制度》（以下简称"《独立董 事工作制度》"）等有关规定和要求，本着客观、公正、独立的原则，勤勉尽责、 独立履职，及时了解公司的生产经营及发展情况，准时出席各次股东大会和董事 会等相关会议，积极发挥独立董事作用，切实维护了公司整体利益和全体股东尤 其是中小股东的合法权益。现将2023年度履职情况报告如下： 一、独立董事的基本情况 （一）个人工作履历、专业背景以及兼职情况 刘桂雄先生，1968年10月生,中国国籍,无境外永久居留权,毕业于重庆大学, 精密仪器及机械专业博士学历。1995年5月至1997年9月,任华南理工大学机电工 程系讲师；1997年9月至2003年4月,任华南理工大学机电工程学院副教授；2003 ...

广州禾信仪器股份有限公司 独立董事关于第三届董事会第二十五次会议相关事项 的独立意见 根据中国证券监督管理委员会《上市公司独立董事管理办法》及《广州禾信 仪器股份有限公司章程》（以下简称"《公司章程》"）、《独立董事工作制度》 的有关规定，作为广州禾信仪器股份有限公司（以下简称"公司"）的独立董事， 本着对公司、全体股东负责的态度，秉持实事求是的原则，我们对公司第三届董 事会第二十五次会议的相关事项进行审查，现发表如下独立意见： 一、关于 2023 年年度利润分配方案的事项 公司 2023 年度利润分配方案充分考虑了公司经营情况、资金需求、股东回 报、未来发展等各种因素，有利于公司持续稳定发展，符合《公司法》《证券法》 《上市公司监管指引第 3 号—上市公司现金分红》以及《公司章程》等规定中关 于利润分配的要求，符合公司实际情况，不存在损害公司及全体股东，尤其是中 小股东利益的情形。 该事项已经董事会审议通过，审议表决程序合法、有效，符合有关法律、法 规及《公司章程》的规定。因此，我们一致同意该事项，并同意提交公司 2023 年 年度股东大会审议。 二、关于 2023 年度募集资金存放与实际使用情况的专项报告 ...

Financial Performance - The company's operating revenue for 2023 was ¥366,178,970.23, representing a year-on-year increase of 30.66% compared to ¥280,256,751.73 in 2022[22]. - The net profit attributable to shareholders for 2023 was -¥96,106,053.43, a decline from -¥63,328,252.80 in 2022[22]. - The cash flow from operating activities for 2023 was -¥36,367,265.30, an improvement from -¥84,580,750.77 in 2022[22]. - The company's total assets increased by 11.25% to ¥1,081,138,237.91 at the end of 2023, up from ¥971,850,182.82 at the end of 2022[22]. - The basic earnings per share for 2023 was -¥1.37, compared to -¥0.90 in 2022[24]. - Operating costs increased by 60.17% to 225.15 million RMB, primarily due to increased revenue and market competition[120]. - The company reported a significant increase in financial expenses by 149.62% to 8.17 million RMB, mainly due to increased borrowing interest[121]. - The gross margin for the instrument manufacturing industry was 38.13%, down 11.40 percentage points compared to the previous year[126]. Corporate Governance - The company has established a governance structure that promotes standardized operations and protects shareholder rights[46]. - The board of directors consists of 9 members, including 3 independent directors, complying with legal requirements[177]. - The supervisory board has 3 members, including 1 employee representative, also meeting legal requirements[178]. - The company held 14 board meetings during the reporting period, ensuring effective decision-making[177]. - The company has no significant differences in governance compared to regulatory requirements[181]. - The company reported a total revenue of 24,075,122, with no significant changes compared to the previous period[188]. Research and Development - The company achieved a total R&D investment of ¥67,559,852.75, a decrease of 13.06% compared to the previous year[84]. - R&D expenses accounted for 18.45% of total revenue, down by 9.28 percentage points from the previous year[85]. - The company obtained 12 new invention patents, 10 utility model patents, and 3 design patents during the reporting period[83]. - The company has successfully industrialized multiple self-developed technologies, including high-stability high-sensitivity inductively coupled plasma discharge technology, which is leading in the domestic market[82]. - The company is focusing on the development of high-precision and high-sensitivity detection technologies to meet market demands[88]. Market Position and Strategy - The company is expanding into medical health, laboratory analysis, and life sciences applications, diversifying its market reach[48]. - The company is actively investing in new product development and market expansion, particularly in the laboratory and medical sectors, which are expected to drive future growth[143]. - The company aims to enhance its core competitiveness and market share in the domestic mass spectrometry market by focusing on R&D and product innovation in various applications including environmental monitoring and food safety[166]. - The company is focusing on R&D for high-value mass spectrometry products across various application fields, including environmental monitoring and healthcare[158]. - The company is committed to improving cost control through better supplier management and supply chain optimization, aiming to reduce procurement costs and improve inventory management[170]. Risks and Challenges - The company faces risks related to potential declines in performance due to increased competition and the need for ongoing R&D investment[102]. - The company is at risk of R&D failures due to the high investment and long cycle associated with mass spectrometry technology development[103]. - The company faces risks related to reliance on government subsidies, which could adversely affect profitability if funding is reduced[113]. - The company is exposed to inventory devaluation risks due to complex product structures and long production cycles[111]. - The company's main revenue source is concentrated in the environmental monitoring sector, posing risks if there are adverse changes in this market[108]. Product Development and Innovation - The company launched several new products in 2023, including the high-resolution quadrupole time-of-flight mass spectrometer LC-QTOF 7000 and the fully automated nucleic acid mass spectrometry detection system NucMass 3000, expanding its product line and application scenarios[52]. - The company has developed and validated multiple core technologies for the domestically produced high-resolution quadrupole time-of-flight mass spectrometer (LC-QTOF 7000) launched in 2023[48]. - The company has developed new mass spectrometer products that integrate AI algorithms and big data, enhancing their application in clinical diagnostics and environmental monitoring[76]. - The company is transitioning from a single equipment provider to a comprehensive service provider to meet diverse customer needs and maintain market competitiveness[78]. - The company has established a comprehensive carbon monitoring solution, integrating site selection, equipment configuration, and data application to support greenhouse gas monitoring and reduction efforts in target cities[58]. Investor Relations and Communication - The company’s financial disclosures are available through various media, including China Securities Journal and Shanghai Securities Journal[18]. - The company’s contact information includes a dedicated email for investor relations and a phone number for inquiries[17]. - The company established information disclosure and investor relations management systems to ensure timely and accurate information dissemination[181]. - A total of 1 annual general meeting and 3 extraordinary general meetings were held, with all resolutions passed without any being rejected[182]. Subsidiaries and Investments - The company has a total of 12 wholly-owned subsidiaries and several equity investees[11]. - The company established a wholly-owned subsidiary, Guangzhou Hexin Technology Co., Ltd., with a registered capital of 20 million RMB, and another subsidiary, Guangzhou Hexin Industrial Park Operation Management Co., Ltd., with a registered capital of 2 million RMB[150]. - The company signed an investment agreement to jointly establish the Guangdong Nano Intelligent Manufacturing Industry Innovation Center with a total investment of 1 billion RMB, with the company's subscribed capital being 20 million RMB[149].

（一）会计师事务所基本情况 致同会计师事务所（特殊普通合伙）前身是成立于 1981 年的北京会计师事务所， 2011 年经北京市财政局批准转制为特殊普通合伙，2012 年更名为致同会计师事务所 （特殊普通合伙）。注册地址为北京市朝阳区建国门外大街 22 号赛特广场 5 层，首 席合伙人为李惠琦。 广州禾信仪器股份有限公司 2023 年度审计委员会对会计师事务所履行监督职责情况报告 广州禾信仪器股份有限公司（以下简称"公司"）聘请致同会计师事务所（特殊 普通合伙）（以下简称"致同"）为公司 2023 年度财务报告和内部控制审计机构。根 据《公司法》《证券法》《上市公司治理准则》《国有企业、上市公司选聘会计师事务 所管理办法》等有关规定和要求，公司审计委员会本着勤勉尽责的原则，对致同 2023 年度审计工作情况履行监督职责，具体如下： 一、2023 年年审会计师事务所基本情况 根据公司《董事会审计委员会议事规则》等有关规定，审计委员会对会计师事务 所履行监督职责的情况如下： （一）审计委员会对致同的专业资质、业务能力、诚信状况、独立性、过往审计 工作情况及其执业质量等进行了严格核查和评价，认为其具备为公司提供审计 ...

广发证券股份有限公司 关于广州禾信仪器股份有限公司 2024 年度日常关联交易预计的核查意见 广发证券股份有限公司（以下简称"广发证券"）作为广州禾信仪器股份有限 公司（以下简称"禾信仪器"或"公司"）的持续督导机构，根据《证券发行上市保 荐业务管理办法》《上海证券交易所科创板上市公司自律监管指引第 1 号——规 范运作》等有关法律法规和规范性文件的要求，就禾信仪器 2024 年度日常关联 交易预计事项进行了核查，核查情况如下： 一、日常关联交易基本情况 （一）日常关联交易履行的审议程序 公司于 2024 年 4 月 15 日召开第三届董事会独立董事专门会议第一次会议， 事前审议了《关于公司 2024 年度日常关联交易预计的议案》，独立董事认为：公 司 2024 年度预计发生的日常关联交易系公司开展日常生产经营所需，相关交易 遵循自愿、平等、互利的原则，参考市场价格确定交易价格，公司主营业务不会 因上述交易而对关联方形成依赖，不会影响公司的独立性，不存在损害公司及股 东利益，特别是中小股东利益的情形。我们一致同意本次日常关联交易预计事项， 并同意提交公司第三届董事会第二十五次会议审议。 公司于 2024 年 ...

广发证券股份有限公司 关于广州禾信仪器股份有限公司 2023 年度募集资金存放与使用情况的核查意见 广发证券股份有限公司（以下简称"广发证券"）作为广州禾信仪器股份有限 公司（以下简称"禾信仪器"或"公司"）的持续督导机构，根据《证券发行上市保 荐业务管理办法》、《上海证券交易所科创板上市公司自律监管指引第 1 号—— 规范运作》、《上市公司监管指引第 2 号——上市公司募集资金管理和使用的监 管要求》、《上海证券交易所科创板股票上市规则》等有关法律法规和规范性文件 的要求，经审慎核查，就禾信仪器 2023 年度募集资金存放与使用情况进行了审 慎核查，发表意见如下： 一、募集资金基本情况 （一）实际募集资金金额和资金到位时间 经中国证券监督管理委员会《关于同意广州禾信仪器股份有限公司首次公开 发行股票注册的批复》（证监许可〔2021〕2320 号）批准，广州禾信仪器股份有 限公司向社会公开发行人民币普通股（A 股）1,750.00 万股，发行价格为 17.70 元/股，募集资金总额为人民币 30,975.00 万元，扣除发行费用（不含增值税）人 民币 3,699.12 万元，实际募集资金净额为人民币 27,2 ...

广州禾信仪器股份有限公司 2023 年度审计委员会履职情况报告 报告期内，广州禾信仪器股份有限公司（以下简称"公司"）审计委员会严 格按照《公司法》《证券法》《上市公司治理准则》《上海证券交易所科创板股票 上市规则》《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》 等有关法律、法规及《公司章程》及《董事会审计委员会议事规则》的规定和要 求，勤勉尽责地履行审计委员会的职责和义务，审慎认真地行使公司、股东和董 事会所赋予的权利，对公司董事会的科学决策、规范运作以及公司发展都起到了 积极作用。现就 2023 年度履职情况汇报如下： 公司第三届审计委员会由陈明先生、刘桂雄先生以及陆万里先生共 3 名成员 组成，召集人由陈明先生担任。审计委员会中独立董事过半数，独立董事陈明先 生为会计专业人士，符合相关法律法规中关于审计委员会人数比例和专业配置的 要求。 2023 年度，审计委员会委员凭借丰富的经验及专业知识，在公司内、外部审 计、审阅公司财务报告、评估内控有效性等工作上向董事会提出了指导性意见， 充分发挥了审计委员会在公司审计和风控管理方面的重要作用。 序号 届次 召开时间 审议事项 表决结果 1 ...